You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
華北製藥(600812.SH):重組人源抗狂犬病毒單抗注射液通過III期臨牀試驗
格隆匯 04-08 21:04

格隆匯4月8日丨華北製藥(600812.SH)公佈,2020年4月8日,公司收到下屬子公司華北製藥集團新藥研究開發有限責任公司(以下簡稱“新藥公司”)的通知,其自主研發的一類新藥重組人源抗狂犬病毒單抗注射液(200IU/瓶,500IU/瓶)完成III期臨牀試驗並取得III期臨牀試驗報告。

試驗結論為:重組人源抗狂犬病毒單抗注射液(rhRIG)聯合人用狂犬病疫苗對III級疑似狂犬病毒暴露人羣的暴露後預防達到主要療效和次要療效終點,且安全性良好,達到方案設定目標,試驗藥物重組人源抗狂犬病毒單抗注射液(rhRIG)是安全、有效的。

重組人源抗狂犬病毒單抗注射液(rhRIG)是新藥公司自主創新項目,被列為國家“重大新藥創制”科技重大專項品種。其作用機制及適應症為將本品與人用狂犬病疫苗聯用,用以補充人用狂犬病疫苗主動免疫過程中的抗體空白,可直接中和體內狂犬病毒,起到被動免疫作用,用於被狂犬或其它狂犬病毒易感動物咬傷、抓傷患者的被動免疫。截至目前,該項目累計研發投入金額為1.46億元。

目前,國內尚無重組抗狂犬病毒單抗藥物上市銷售。國內可用於狂犬病毒暴露後預防的被動免疫製劑為抗狂犬病血清和狂犬病人免疫球蛋白。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account